

Haralabos P Kalofonos

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3969382/haralabos-p-kalofonos-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

276
papers

8,056
citations

47
h-index

77
g-index

283
ext. papers

9,248
ext. citations

4.3
avg, IF

5.57
L-index

#	Paper	IF	Citations
276	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1688-1700	21.7	328
275	Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. <i>Blood</i> , 2008 , 112, 1593-9	2.2	316
274	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1218-1230	59.2	294
273	A review on oxaliplatin-induced peripheral nerve damage. <i>Cancer Treatment Reviews</i> , 2008 , 34, 368-77	14.4	244
272	Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2396-403	2.2	241
271	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. <i>Annals of Oncology</i> , 2013 , 24, 454-462	10.3	191
270	Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. <i>Cancer Management and Research</i> , 2014 , 6, 135-47	3.6	179
269	Peripheral nerve damage associated with administration of taxanes in patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 218-28	7	170
268	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 447-56	4.4	149
267	Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. <i>Cancer</i> , 2013 , 119, 438-44	6.4	142
266	Financial crisis and austerity measures in Greece: their impact on health promotion policies and public health care. <i>Health Policy</i> , 2013 , 113, 8-12	3.2	126
265	Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. <i>Cancer</i> , 2009 , 115, 1544-54	6.4	114
264	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. <i>Annals of Oncology</i> , 2014 , 25, 257-64	10.3	112
263	A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. <i>Supportive Care in Cancer</i> , 2006 , 14, 1134-40	3.9	108
262	Either called "chemobrain" or "chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real. <i>Journal of Pain and Symptom Management</i> , 2011 , 41, 126-39	4.8	107
261	Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. <i>Journal of Pain and Symptom Management</i> , 2006 , 32, 237-44	4.8	96
260	Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. <i>Gynecologic Oncology</i> , 2005 , 97, 436-41	4.9	93

259	Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. <i>Cancer</i> , 2004 , 101, 404-11	6.4	92
258	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 392-8	5.5	91
257	Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 939-44	2.2	90
256	Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). <i>Annals of Oncology</i> , 2001 , 12, 1231-8	10.3	86
255	Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005 , 16, 1762-71	10.3	84
254	Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. <i>Breast Cancer Research and Treatment</i> , 2006 , 97, 237-44	4.4	78
253	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. <i>Cancer</i> , 2013 , 119, 3570-7	6.4	69
252	Intratumoral doxorubicin in patients with malignant brain gliomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, 60-4	2.7	68
251	Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. <i>Acta Oncologica</i> , 2007 , 46, 1131-7	3.2	67
250	Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011 , 459, 431-40	5.1	64
249	A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 87-99	4.4	64
248	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. <i>Neurotherapeutics</i> , 2018 , 15, 178-189	6.4	63
247	The upgraded role of HER3 and HER4 receptors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 73-8	7	62
246	Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?. <i>Supportive Care in Cancer</i> , 2006 , 14, 223-9	3.9	59
245	Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2004 , 15, 1517-26	10.3	59
244	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 3116-3122	10.3	56
243	Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. <i>Oncology</i> , 2009 , 77, 1-11	3.6	55
242	Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. <i>International Journal of Cancer</i> , 2003 , 104, 155-60	7.5	55

241	Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. <i>Annals of Oncology</i> , 2005 , 16, 869-77 ^{10,3}	54
240	Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2002 , 13, 1737-42	10.3 54
239	Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 131-43	4.4 53
238	Information needs and awareness of diagnosis in patients with cancer receiving chemotherapy: a report from Greece. <i>Palliative Medicine</i> , 2002 , 16, 315-21	5.5 53
237	The informational needs, satisfaction with communication, and psychological status of primary caregivers of cancer patients receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2001 , 9, 591-6	3.9 52
236	Bortezomib-induced peripheral neurotoxicity: an update. <i>Archives of Toxicology</i> , 2014 , 88, 1669-79	5.8 51
235	Characterization and Biological Evaluation of Propolis from Poland. <i>Molecules</i> , 2017 , 22,	4.8 51
234	Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>British Journal of Cancer</i> , 2008 , 99, 1775-85	8.7 50
233	Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. <i>Pharmacogenomics Journal</i> , 2012 , 12, 468-75	3.5 49
232	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , 2014 , 19, 299-306	4.7 48
231	Brain metastasis in renal cell cancer responding to sunitinib. <i>Anticancer Research</i> , 2007 , 27, 4255-7	2.3 48
230	Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?. <i>Supportive Care in Cancer</i> , 2005 , 13, 647-51	3.9 47
229	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019 , 30, 766-773	10.3 46
228	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, LBA1-LBA1	2.2 44
227	Autophagy: novel action of panitumumab in colon cancer. <i>Anticancer Research</i> , 2009 , 29, 5077-82	2.3 41
226	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. <i>Annals of Oncology</i> , 2008 , 19, 853-60	10.3 40
225	Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. <i>European Journal of Cancer Care</i> , 2007 , 16, 231-7	2.4 40
224	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 609-19	4.4 39

223	Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. <i>BMC Cancer</i> , 2011 , 11, 314	4.8	39
222	The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. <i>Melanoma Research</i> , 2004 , 14, 289-94	3.3	39
221	Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2008 , 19, 115-22	10.3	38
220	Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. <i>Gynecologic Oncology</i> , 2004 , 95, 695-700	4.9	38
219	Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005 , 16, 950-7	10.3	37
218	The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. <i>Strahlentherapie Und Onkologie</i> , 2004 , 180, 201-8	4.3	36
217	POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance?. <i>Anticancer Research</i> , 2008 , 28, 1221-7	2.3	36
216	Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 237-47	7	35
215	Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours. <i>Histopathology</i> , 2006 , 49, 582-93	7.3	35
214	ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance. <i>Cancer Genomics and Proteomics</i> , 2018 , 15, 127-141	3.3	35
213	A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 791-803	3.5	34
212	Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). <i>Cancer Investigation</i> , 2004 , 22, 655-62	2.1	34
211	Impact of cancer on primary caregivers of patients receiving radiation therapy. <i>Acta Oncologica</i> , 2001 , 40, 766-71	3.2	34
210	Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. <i>Oncology</i> , 2009 , 76, 275-85	3.6	33
209	A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. <i>BMC Medicine</i> , 2010 , 8, 3	11.4	33
208	A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. <i>BMC Medicine</i> , 2011 , 9, 10	11.4	32
207	Enhancement of TGF- β signaling responses by the E3 ubiquitin ligase Arkadia provides tumor suppression in colorectal cancer. <i>Cancer Research</i> , 2011 , 71, 6438-49	10.1	32
206	EGFR, HER-2 and COX-2 levels in colorectal cancer. <i>Histopathology</i> , 2008 , 53, 698-706	7.3	32

205	Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. <i>Journal of Pain and Symptom Management</i> , 2003 , 25, 512-8	4.8	32
204	Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 23-31	4.8	31
203	Physicians' brain drain in Greece: a perspective on the reasons why and how to address it. <i>Health Policy</i> , 2014 , 117, 210-5	3.2	30
202	bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2001 , 9, 329-34	1.9	30
201	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 899-902	3.5	29
200	A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2005 , 35, 103-9		29
199	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. <i>Breast Cancer Research and Treatment</i> , 2005 , 92, 1-9	4.4	29
198	Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2001 , 12, 1417-22	10.3	29
197	Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. <i>Journal of Pain and Symptom Management</i> , 2017 , 54, 701-706.e1	4.8	28
196	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. <i>Journal of the Peripheral Nervous System</i> , 2015 , 20, 15-23	4.7	28
195	Identification of novel human receptor activator of nuclear factor- κ B isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. <i>Breast Cancer Research</i> , 2012 , 14, R112	8.3	28
194	Epothilone-induced peripheral neuropathy: a review of current knowledge. <i>Journal of Pain and Symptom Management</i> , 2011 , 42, 931-40	4.8	28
193	Antiproliferative effect of exemestane in lung cancer cells. <i>Molecular Cancer</i> , 2009 , 8, 109	42.1	28
192	Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. <i>International Journal of Cancer</i> , 2002 , 102, 86-90	7.5	28
191	LIMK/cofilin pathway and Slingshot are implicated in human colorectal cancer progression and chemoresistance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 472, 727-737	5.1	26
190	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. <i>Journal of the Peripheral Nervous System</i> , 2014 , 19, 127-35	4.7	26
189	Lapatinib-induced hepatitis: a case report. <i>World Journal of Gastroenterology</i> , 2011 , 17, 2349-52	5.6	26
188	Association of FOXP3 expression with non-small cell lung cancer. <i>Anticancer Research</i> , 2011 , 31, 1677-832.3		26

187	Molecularly targeted therapies for malignant gliomas. <i>Molecular Medicine</i> , 2009 , 15, 115-22	6.2	25
186	Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?. <i>European Journal of Neurology</i> , 2010 , 17, 963-8	6	25
185	A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. <i>Annals of Oncology</i> , 1997 , 8, 1213-20	10.3	25
184	Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. <i>Histology and Histopathology</i> , 2010 , 25, 299-307	1.4	25
183	Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem. <i>Journal of Breast Cancer</i> , 2015 , 18, 207-17	3	24
182	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. <i>European Journal of Neurology</i> , 2013 , 20, 788-94	6	24
181	Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance?. <i>International Journal of Colorectal Disease</i> , 2009 , 24, 613-22	3	24
180	HER-3 in colorectal tumorigenesis: from mRNA levels through protein status to clinicopathologic relationships. <i>European Journal of Cancer</i> , 2007 , 43, 2602-11	7.5	24
179	Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 69, 199-210	7	23
178	An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. <i>Investigational New Drugs</i> , 2010 , 28, 554-60	4.3	23
177	Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. <i>Journal of Neurology</i> , 2005 , 252, 1459-64	5.5	23
176	Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in colorectal cancer: prognostic significance and clinicopathologic correlations. <i>Cellular Oncology</i> , 2009 , 31, 235-47		23
175	Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. <i>Current Medicinal Chemistry</i> , 2009 , 16, 3797-804	4.3	22
174	Hepatocellular carcinoma metastasis in the pituitary gland: case report and review of the literature. <i>Journal of Neuro-Oncology</i> , 2003 , 63, 173-7	4.8	22
173	Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 523-530	4.5	22
172	KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. <i>BMJ Open</i> , 2014 , 4, e004652	3	21
171	Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. <i>Acta Oncologica</i> , 2008 , 47, 1148-55	3.2	21
170	Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 277-84	3.5	21

169	Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study. <i>Digestive Diseases and Sciences</i> , 2003 , 48, 1990-7	4	21
168	Radioimmunosintigraphy in patients with ovarian cancer. <i>Acta Oncologica</i> , 2001 , 40, 549-57	3.2	21
167	Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000 , 23, 83-8	2.7	21
166	Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours. <i>BioMed Research International</i> , 2013 , 2013, 214864	3	20
165	Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Annals of Oncology</i> , 2009 , 20, 1362-8	10.3	20
164	Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. <i>Annals of Oncology</i> , 2003 , 14, 1094-9	10.3	20
163	Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients survival. <i>In Vivo</i> , 2014 , 28, 315-26	2.3	20
162	The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. <i>Cellular Oncology (Dordrecht)</i> , 2011 , 34, 381-91	7.2	19
161	Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2006 , 17, 1560-7	10.3	19
160	Monoclonal antibodies in the management of solid tumors. <i>Current Topics in Medicinal Chemistry</i> , 2006 , 6, 1687-705	3	18
159	. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 2001 , 9, 329-334		18
158	TGF-beta repressors SnoN and Ski are implicated in human colorectal carcinogenesis. <i>Cellular Oncology</i> , 2009 , 31, 41-51		18
157	ILK overexpression in human hepatocellular carcinoma and liver cirrhosis correlates with activation of Akt. <i>Oncology Reports</i> , 2008 , 20, 1337-44	3.5	18
156	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019 , 24, 491-497	5.7	17
155	Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach. <i>Human Genomics</i> , 2015 , 9, 12	6.8	17
154	NSCLC and the alternative pathway of NF-B: uncovering an unknown relation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012 , 460, 515-23	5.1	17
153	Dual targeting of EGFR and HER-2 in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 973-81	3.5	17
152	Medical students' views of undergraduate Oncology education: A comparative study. <i>Education for Health: Change in Learning and Practice</i> , 2006 , 19, 61-70	0.4	17

151	Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Annals of Oncology</i> , 2005 , 16, 1116-22	10.3	17
150	Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 1999 , 10, 475-8	10.3	17
149	The Survivin B1 Snp in Human Colorectal Cancer Correlates with Survivin Splice Variant Expression and Improved Overall Survival. <i>Analytical Cellular Pathology</i> , 2010 , 33, 177-189	3.4	16
148	Targeted therapy in colorectal cancer: current status and future challenges. <i>Current Medicinal Chemistry</i> , 2011 , 18, 1599-612	4.3	16
147	Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>European Journal of Cancer</i> , 2008 , 44, 2169-77	7.5	16
146	A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 51-9	3.5	16
145	Impact of providing booklets about chemotherapy to newly presenting patients with cancer: a randomized controlled trial. <i>Annals of Oncology</i> , 2006 , 17, 515-20	10.3	16
144	Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. <i>Anticancer Research</i> , 2005 , 25, 3103-8	2.3	16
143	Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patientsPoutcome. <i>In Vivo</i> , 2007 , 21, 113-8	2.3	16
142	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020 , 25, 171-177	4.7	15
141	Altered expression of NFY-C and RORA in colorectal adenocarcinomas. <i>Acta Histochemica</i> , 2012 , 114, 553-61	2	15
140	Bevacizumab in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2010 , 36, 75-82	14.4	15
139	Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <i>Oncology</i> , 2007 , 72, 388-96	3.6	15
138	An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 45, 265-75	7	15
137	Capecitabine-induced hypertriglyceridemia: a report of two cases. <i>Anticancer Research</i> , 2006 , 26, 2249-51.3	5.1	15
136	Focal Adhesion Proteins Band PParvin are Overexpressed in Human Colorectal Cancer and Correlate with Tumor Progression. <i>Cancer Investigation</i> , 2015 , 33, 387-97	2.1	14
135	The Fire Within: NF-B Involvement in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020 , 80, 4025-4036	10.1	14
134	Expression patterns of SDF1/CXCR4 in human invasive breast carcinoma and adjacent normal stroma: correlation with tumor clinicopathological parameters and patient survival. <i>Pathology Research and Practice</i> , 2014 , 210, 662-7	3.4	14

133	Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group. <i>Clinical Breast Cancer</i> , 2010 , 10, 230-37	14
132	Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression. <i>Cancer Letters</i> , 2006 , 244, 34-41	9.9 14
131	RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF- κ B activation and EGFR signaling. <i>Oncogene</i> , 2018 , 37, 5101-5114	9.2 14
130	The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins. <i>Anticancer Research</i> , 2010 , 30, 4987-92	2.3 14
129	Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells. <i>Journal of Biomedical Science</i> , 2015 , 22, 98	13.3 13
128	Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. <i>Oncology</i> , 2009 , 77, 254-6	3.6 13
127	Prognostic significance of Dicer cellular levels in soft tissue sarcomas. <i>Cancer Investigation</i> , 2012 , 30, 172-9	2.1 13
126	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. <i>Supportive Care in Cancer</i> , 2018 , 26, 3143-3151	3.9 12
125	Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection. <i>Human Genomics</i> , 2013 , 7, 14	6.8 12
124	Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. <i>Molecular Medicine</i> , 2009 , 15, 183-91	6.2 12
123	Religiosity and its relation to quality of life in Christian Orthodox cancer patients undergoing chemotherapy. <i>Psycho-Oncology</i> , 2009 , 18, 284-9	3.9 12
122	Prion protein expression and the M129V polymorphism of the PRNP gene in patients with colorectal cancer. <i>Molecular Carcinogenesis</i> , 2010 , 49, 693-9	5 12
121	Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. <i>Gynecologic Oncology</i> , 2008 , 110, 87-92	4.9 12
120	The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. <i>Analytical Cellular Pathology</i> , 2010 , 33, 177-89	3.4 12
119	Multiple primary malignancies: a report of two cases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014 , 26, 215-8	3.8 12
118	Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 853-858	5.7 12
117	Patients and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24, 111-119	4.7 11
116	The exposure of breast cancer cells to Fulvestrant and tamoxifen modulates cell migration differently. <i>BioMed Research International</i> , 2013 , 2013, 147514	3 11

115	Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Oncology Reports</i> , 2012 , 27, 216-24	3.5	11
114	Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG). <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 207-12	3.5	11
113	Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 161-74	4.4	11
112	A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2002 , 98, 141-7	7.5	11
111	Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005 , 16, 773-9	10.3	11
110	Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. <i>Supportive Care in Cancer</i> , 2020 , 28, 1991-1995	3.9	11
109	Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2015 , 89, 311-9	5.9	10
108	Alternative splicing generates a truncated isoform of human TNFRSF11A (RANK) with an altered capacity to activate NF- κ B. <i>Gene</i> , 2013 , 525, 124-9	3.8	10
107	RANK and EGFR in invasive breast carcinoma. <i>Cancer Genetics</i> , 2017 , 216-217, 61-66	2.3	10
106	Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 189-93	2.8	10
105	Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions. <i>Current Medicinal Chemistry</i> , 2011 , 18, 1584-98	4.3	10
104	Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study. <i>Gastric Cancer</i> , 2006 , 9, 26-31	7.6	10
103	The impact of paclitaxel or cisplatin-based chemotherapy on sympathetic skin response: a prospective study. <i>European Journal of Neurology</i> , 2005 , 12, 858-61	6	10
102	and Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	10
101	Assessment of sexual function in patients with cancer undergoing radiotherapy--a single centre prospective study. <i>Anticancer Research</i> , 2012 , 32, 657-64	2.3	10
100	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24, 298-303	4.7	9
99	Vitamin E for preventing chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2011 , 19, 725-6; author reply 727-8	3.9	9
98	Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with better [corrected] prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009 , 454, 41-53	5.1	9

97	Estrogen signaling in colorectal carcinoma microenvironment: expression of ERbeta1, AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009 , 454, 389-99	5.1	9
96	Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group. <i>Cancer Investigation</i> , 2004 , 22, 832-9	2.1	9
95	Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. <i>Anticancer Research</i> , 2008 , 28, 2913-20	2.3	9
94	Expression Of Intracellular Components of the NF-B Alternative Pathway (NF-B2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients. <i>Scientific Reports</i> , 2019 , 9, 14299	4.9	8
93	Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTB is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	8
92	Differentially Methylated Ultra-Conserved Regions Uc160 and Uc283 in Adenomas and Adenocarcinomas Are Associated with Overall Survival of Colorectal Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	8
91	The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines. <i>Pharmaceutical Biology</i> , 2013 ,	3.8	8
90	Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 509-11	4.8	8
89	Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). <i>Annals of Oncology</i> , 2011 , 22, 827-834	10.3	8
88	Angiogenesis as a therapeutic target in breast cancer. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012 , 12, 1239-8	3.8	8
87	Oval cell proliferation in cirrhosis in rats. An experimental study. <i>Hepatology Research</i> , 2007 , 37, 755-64	5.1	8
86	A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, 22-26	2.7	8
85	Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their value for detection of adenomas and adenocarcinomas. <i>Oncotarget</i> , 2018 , 9, 21411-21428	3.3	8
84	Ionizing radiation affects epidermal growth factor receptor signalling and metalloproteinase secretion in glioma cells. <i>Cancer Genomics and Proteomics</i> , 2011 , 8, 33-8	3.3	8
83	Regioselective chemical and rapid enzymatic synthesis of a novel redox Antiproliferative molecular hybrid. <i>European Journal of Medicinal Chemistry</i> , 2015 , 96, 47-57	6.8	7
82	NF-kB2 Genetic Variations are Significantly Associated with Non-Small Cell Lung Cancer Risk and Overall Survival. <i>Scientific Reports</i> , 2018 , 8, 5259	4.9	7
81	Large cell neuroendocrine carcinoma of the lung metastatic to the shoulder joint, causing suprascapular nerve palsy. <i>Journal of Pain and Symptom Management</i> , 2011 , 42, e1-3	4.8	7
80	VEGF polymorphisms may be associated with susceptibility to colorectal cancer: a case-control study. <i>Cancer Biomarkers</i> , 2011 , 10, 213-7	3.8	7

79	Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. <i>European Journal of Cancer Care</i> , 2008 , 17, 535-41	2.4	7
78	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1289-301	3.5	6
77	Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2020 , 25, 178-183	4.7	6
76	Positive association between two polymorphic sites (+134 insA/delA and G198T) of the endothelin-1 gene and chronic obstructive pulmonary disease. A case-control study. <i>Respiratory Medicine</i> , 2010 , 104, 114-20	4.6	6
75	The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. <i>Urology</i> , 2005 , 66, 382-5	1.6	6
74	A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma. <i>Cancer Investigation</i> , 2003 , 21, 855-62	2.1	6
73	Monoclonal antibodies. Future potential in cancer chemotherapy. <i>Drugs</i> , 1989 , 38, 645-57	12.1	6
72	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021 , 97, e660-e672	6.5	6
71	Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study. <i>Anticancer Research</i> , 2003 , 23, 1687-91	2.3	6
70	Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study. <i>Anticancer Research</i> , 2019 , 39, 1403-1409	2.3	5
69	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial. <i>British Journal of Cancer</i> , 2020 , 123, 355-361	8.7	5
68	Clonal rearrangement of the T-cell receptor gamma gene associated with a bizarre lymphoproliferative syndrome. <i>European Journal of Haematology</i> , 1988 , 41, 289-94	3.8	5
67	Paclitaxel, topotecan, and carboplatin in metastatic endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. <i>Gynecologic Oncology</i> , 2008 , 111, 27-34	4.9	5
66	Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. <i>Acta Oncologica</i> , 2008 , 47, 1171-3	3.2	5
65	Adriamycin and cis-platinum as first-line treatment in unresectable locally advanced or metastatic adult soft-tissue sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 307-11	2.7	5
64	Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). <i>Anti-Cancer Drugs</i> , 2004 , 15, 479-87	2.4	5
63	Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56, 521-8	3.5	5
62	Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 164, 690-697	3.5	5

61	Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival. <i>Journal of Molecular Histology</i> , 2020 , 51, 385-400	3.3	4
60	Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib. <i>OncoTargets and Therapy</i> , 2017 , 10, 4885-4893	4.4	4
59	Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer. <i>Cancer Investigation</i> , 2001 , 19, 137-44	2.1	4
58	Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, 591-6	2.7	4
57	The role of monoclonal antibodies in tumour diagnosis. <i>Cancer Treatment Reviews</i> , 1986 , 13, 243-52	14.4	4
56	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e526-e533	3.3	3
55	The Impact of Anti-tumor Agents on ER-Positive MCF-7 and HER2-Positive SKBR-3 Breast Cancer Cells Biomechanics. <i>Annals of Biomedical Engineering</i> , 2019 , 47, 1711-1724	4.7	3
54	PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.	6.6	3
53	Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1092, 515-523	3.2	3
52	Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel. <i>Pharmacogenomics Journal</i> , 2014 , 14, 248-55	3.5	3
51	Current therapeutic leads for the treatment of melanoma: targeted immunotherapy in the post-genomic era. <i>Current Molecular Pharmacology</i> , 2014 , 7, 33-43	3.7	3
50	Cardiovascular effects of treatment with taxanes. <i>Journal of Cardiovascular Medicine</i> , 2012 , 13, 319-24	1.9	3
49	Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. <i>Medical Oncology</i> , 2007 , 24, 301-7	3.7	3
48	Absence of chemotherapy-induced alopecia with paclitaxel in a case of hypothyroidism: case report. <i>Annals of Oncology</i> , 2003 , 14, 1690-1	10.3	3
47	Mitomycin C and Vinblastine in Anthracycline-resistant Metastatic Breast Cancer: A Phase II Study. <i>Tumori</i> , 2001 , 87, 394-397	1.7	3
46	Iris Metastasis in a Patient With Small Cell Lung Cancer: A Case Report. <i>Iranian Red Crescent Medical Journal</i> , 2016 , 18, e21522	1.3	3
45	Design, synthesis and evaluation of an anthraquinone derivative conjugated to myelin basic protein immunodominant (MBP) epitope: Towards selective immunosuppression. <i>European Journal of Medicinal Chemistry</i> , 2018 , 143, 621-631	6.8	3
44	Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. <i>International Journal of Neuroscience</i> , 2020 , 1-6	2	3

43	Pilot study of nitric oxide-donating aspirin in patients with pancreatic cancer pain. <i>The Journal of Supportive Oncology</i> , 2006 , 4, 168		3
42	Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
41	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. <i>ESMO Open</i> , 2020 , 5,	6	2
40	Three Regioselectively Acylated Flavonoid Aglycone Derivatives in Equimolar Yield at One Blow. <i>ChemistrySelect</i> , 2018 , 3, 5207-5211	1.8	2
39	Mitogen-activated protein kinases in gliomas and correlation with patientsPprognosis. <i>Acta Neurologica Scandinavica</i> , 2014 , 129, 226-233	3.8	2
38	Everolimus as second-line treatment in metastatic renal cell carcinoma (mRCC) after first-line pazopanib (The RESCUE study): A retrospective analysis by the Hellenic GU Cancer Group (HGUCG) with international collaboration.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15601-e15601	2.2	2
37	The clinical significance of NF- κ B, RelB, NIK, and BCL3 expression in NSCLC.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e18511-e18511	2.2	2
36	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 239-241	1.4	2
35	Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	2
34	Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2021 , 26, 43-48	4.7	2
33	In Reply. <i>Oncologist</i> , 2020 , 25, e2023	5.7	1
32	Ulcerative colitis six years after colon cancer: only a coincidence?. <i>International Medical Case Reports Journal</i> , 2014 , 7, 85-8	1	1
31	Seasonal variability in the incidence of carcinomatous meningitis. <i>Journal of Neurosurgery</i> , 2015 , 122, 543-6	3.2	1
30	Promises and hurdles of undergraduate medical development in Greece. <i>Advances in Medical Education and Practice</i> , 2011 , 2, 201-8	1.5	1
29	Myelotoxicity in cancer patients treated with chemotherapy: negative or positive prognostic factor?. <i>Clinical Cancer Research</i> , 2008 , 14, 7579	12.9	1
28	A case of chondrosarcoma developing in a recurrent retroperitoneal mass after chemotherapy for testicular germ cell tumor. <i>Urologia Internationalis</i> , 2006 , 77, 86-8	1.9	1
27	A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS). <i>Sarcoma</i> , 2004 , 8, 129-133	3.1	1
26	Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 57-67	2.7	1

25	PIOS ratio: predicting the best response of non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21507-e21507	2.2	1
24	A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS). <i>Sarcoma</i> , 2004 , 8, 129-33	3.1	1
23	TGF- β Repressors SnoN and Ski Are Implicated in Human Colorectal Carcinogenesis. <i>Analytical Cellular Pathology</i> , 2009 , 31, 41-51	3.4	1
22	Hepatocellular carcinoma in hepatectomized patients: biologic and therapeutic implications. <i>Anticancer Research</i> , 2005 , 25, 3067-73	2.3	1
21	Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. <i>Anticancer Research</i> , 2010 , 30, 4325-33 ³	3.3	1
20	Prospectively Assessing Serum Neurofilament Light Chain Levels As A Biomarker Of Paclitaxel-Induced Peripheral Neurotoxicity In Breast Cancer Patients.. <i>Journal of the Peripheral Nervous System</i> , 2022 ,	4.7	1
19	Prospective assessment of psychopathological symptoms and their relation to demographic factors in primary caregivers of cancer patients throughout chemotherapy. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	0
18	NF- β 2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development. <i>Translational Oncology</i> , 2021 , 14, 100912	4.9	0
17	Radiotherapy and Renal Cell Carcinoma: A Continuing Saga. <i>In Vivo</i> , 2021 , 35, 1365-1377	2.3	0
16	Genetic Variations of and Genes Are Associated With Increased Susceptibility and Clinical Outcome of Non-Small-Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2021 , 11, 721577	5.3	0
15	Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine. <i>Current Signal Transduction Therapy</i> , 2009 , 4, 6-21	0.8	
14	The alternative NF- β pathway in colorectal cancer: From genetic polymorphisms through mRNA to protein levels.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15619-e15619	2.2	
13	VEGF-A polymorphisms affect the pharmacologic effect of bevacizumab on VEGF-A levels in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15505-e15505	2.2	
12	Evaluation of NF- β 2 polymorphisms rs7897947, rs11574852 and rs12769316 in NSCLC: A case-control study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22044-e22044	2.2	
11	Patterns of practice in the management of advanced urothelial cancer (UC) in Greece: A retrospective analysis by the hellenic GU Cancer Group (HGUCG).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15514-e15514	2.2	
10	RANK/EGFR interplay in breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e13011-e13011	2.2	
9	NF- β SNPs, rs7897947, and rs12769316 and survival outcome of NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e13012-e13012	2.2	
8	Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their diagnostic and prognostic value.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15130-e15130	2.2	

- | | | |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 7 | Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9090-9090 | 2.2 |
| 6 | BCL3 and NSCLC: Are they related?. <i>Journal of Clinical Oncology</i> , 2013 , 31, e18507-e18507 | 2.2 |
| 5 | Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920946152 | 5.4 |
| 4 | Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21164-e21164 | 2.2 |
| 3 | Lack of association of the M129V polymorphism of the PRNP gene with pseudoexfoliation syndrome. <i>Clinical Ophthalmology</i> , 2016 , 10, 731-4 | 2.5 |
| 2 | Identification of a seasonal pattern to brain metastases. <i>Neuropsychiatric Disease and Treatment</i> , 2016 , 12, 609-10 | 3.1 |
| 1 | Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports. <i>Molecular and Clinical Oncology</i> , 2016 , 5, 803-806 | 1.6 |